Tuberculosis Surveillance in Europe EuroTB update March 2008 WHO Collaborating Centre.
-
Upload
cecily-barnett -
Category
Documents
-
view
215 -
download
0
Transcript of Tuberculosis Surveillance in Europe EuroTB update March 2008 WHO Collaborating Centre.
Tuberculosis Surveillance in Europe
EuroTB
update March 2008
WHO Collaborating Centre
About EuroTB, 1996-2007EuroTB was set up in 1996 to develop and
coordinate a European network of national tuberculosis surveillance institutions in the 53 countries of the WHO European Region. The project was based at the Institut de veille sanitaire (InVS) in France, and was financially supported by the European Commission. The mission statement of EuroTB was to improve the contribution of surveillance to tuberculosis control in the European Region. EuroTB promoted the standardisation of surveillance methods. Its mainstay was the collection and validation of national epidemiological information on tuberculosis, including drug resistance and treatment outcome. The main outputs were an annual report, scientific articles, oral communications and data dissemination on www.eurotb.org. Data presented here are the latest available at the end of the project in December 2007.
EUROPEAN UNION (EU) (dark blue)AustriaBelgiumBulgariaCyprusCzech RepublicDenmarkEstoniaFinlandFranceGermanyGreeceHungaryIrelandItalyLatviaLithuaniaLuxembourgMaltaNetherlandsPolandPortugalRomaniaSlovakiaSloveniaSpainSwedenUnited Kingdom
WEST, non-EU (light blue)AndorraIcelandIsraelMonacoNorwaySan MarinoSwitzerland
BALKANS (yellow)AlbaniaBosnia & HerzegovinaCroatiaMacedonia, F.Y.RMontenegroSerbiaTurkey
EAST (orange)ArmeniaAzerbaijanBelarusGeorgiaKazakhstanKyrgyzstanMoldovaRussian FederationTajikistanTurkmenistanUkraineUzbekistan
WHO European Region, 2008
Case-based reporting to EuroTB in 2007
Andorra
Malta
Monaco
San Marino
Not included or not reporting to EuroTB
No case-based reporting (aggregate only)
Case-based notification data only
Case-based data, including drug resistance
Case-based data, including drug resistance and outcome*
* No case-based data for drug resistance in Greece and Poland. Outcome data in Greece started in report year 2006.
*
*
European definitions for TB surveillance (1)
Definite case* A patient with culture-confirmed TB disease due to Mycobacterium
tuberculosis complex. In countries where culture is not routine:
a patient with positive sputum smear
Other-than-
definite case*
A patient with clinical and/or radiological signs compatible with TB
and
clinician’s decision to treat with full treatment
Notifiable TB
case*
All definite and other-than-definite TB cases notified in the calendar
year of interest should be notified. Cases should only be counted
once in a given calendar year.
New case A patient who has never had treatment for TB in the past or who has
taken anti-TB drugs for less than one month.
Retreated case A patient previously treated for TB with combination chemotherapy for
4 weeks or more, excluding prophylactic therapy.
* In the new definitions proposed by the European Centre for Disease Prevention and Control, “definite” and “other-than-definite” will be replaced by “possible” (based only on clinical criteria or post-mortem findings), “probable” (if there is additional detection of acid-fast bacilli or granulomata or M.tb complex nucleic acid) or “confirmed” (by culture, or nucleic acid+AFB). All three categories will be subject to reporting, as well as cases reported only by laboratories without information on clinical criteria.
Pulmonary case A patient with TB of the lung parenchyma or the tracheo-bronchial tree (including larynx).
Extra-pulmonary case A patient with TB of organs other than the lungs or the tracheo-bronchial tree
Note: a patient with both pulmonary and extra-pulmonary TB is classified as pulmonary.
Primary drug resistance Resistance to one or more anti-TB drugs at start of treatment in a new TB case
Acquired drug resistance
Resistance to one or more anti-TB drugs at start of treatment in a retreated TB case
Multi-drug resistance (MDR)
Resistance to at least isoniazid and rifampicin
Extensive drug resistance (XDR)
MDR and
1) resistance to a fluoroquinolone and
2) resistance to one or more of the following injectable drugs: amikacin, capreomycin, or kanamycin
European definitions for TB surveillance (2)
Cured Treatment completion and:
-culture becoming negative on samples taken at the end of treatment and on at least one previous occasion, or
- sputum microscopy becoming negative for AFB at the end of treatment and on at least one previous occasion
Completed Treatment completion, not meeting the criteria to be classified as cure or treatment failure
Died Death before starting treatment or during treatment, irrespective of cause (including post-mortem diagnosis)
Failed Culture or sputum microscopy remaining positive or becoming positive again at 5 months or later during treatment
Defaulted Treatment interrupted for 2 consecutive months or more
Transferred Patient referral to another clinical unit for treatment and information on outcome not available / not obtained
Still on treatment
Patient still on treatment at 12 months and who did not meet any other outcome during treatment, including patients with:
- treatment prolonged because of side effects / complications, initial regimen planned for > 12 months
- initial treatment changed due to polyresistance (ie. resistance to at least two first line drugs) on the isolate taken at the start of treatment
- information on the reasons for being still on treatment not available
Unknown information on outcome not available
European definitions for TB surveillance (3) Treatment outcome categories (from 2001 cohorts)
Cohort All definite pulmonary cases notified in one calendar
year and followed up for TOM. Cohorts in use for
TOM are either smear positive or culture positive
(depending on the country of report) and stratified by
treatment history - new, retreated and unknown.
Period of
observation
Maximal duration of time from start of treatment or
registration for observing treatment outcome. This is
set at 12 months.
European definitions for TB surveillance (4)Cohort analysis for treatment outcome monitoring (TOM)
Source: WHO, 2008
No report
0–24
25–49
50–99
100 or more
* Notified TB cases (new and relapse) per 100 000 population
Tuberculosis notification rates (1)World, 2006*
The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2006. All rights reserved
Tuberculosis notification rates (2) WHO European Region, 2006
TB cases per 100 000 population
Not includedNot reporting to EuroTB< 11 11 – 20 21 – 50> 50
Andorra
Malta
Monaco
San Marino
Tuberculosis notification rates (3) Trends by areas, 1996-2006
0
20
40
60
80
100
120
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
TB cases/100 000
East
European Region
Balkans
EU-27 & West
EU-15
Tuberculosis notification rates (4) Mean annual change in rate, 1998-2006*
* Excluding Monaco, San Marino (EU & West)
-10%
-5%
0%
5%
10%
1998-2002 2002-2006
% change in rate
EU & West Balkans East
Tuberculosis notification rates (5) Pulmonary smear positive rates, 2006
5
* Country range shown in brackets. Excluding countries with missing data (Monaco, San Marino) or using the respiratory classification (Belarus, Bulgaria)
(1-68)0
10
15
20
25
30
35
40Sputum smear positive
TB cases / 100 000
EU & West
Balkans
East
(6-15) (27-117)
Percentage of TB cases of foreign origin, 2006
AndorraMalta Monaco San Marino
Not included or not reporting to EuroTB0% – 4% 5% – 19% 20% – 49%> 49%
TB cases with positive culture, 2006*
(28-100%) (28-63%) (4-36%)Andorra
Malta
Monaco
San Marino
Percentage of TB cases with positive culture
Not included or no culture data reported to EuroTB
< 40%
40% – 54%
55% – 74%
> 74%
* Data from 2005 for Ireland and Romania (culture results incomplete in 2006)
TB cases with primary MDR, 2006*
AndorraMalta Monaco San Marino
Percentage of new TB cases with MDRNot included or not reporting to EuroTBNo nationwide data on drug resistance reported0.0% – 0.9% 1.0% – 1.9%2.0% – 5.9%6.0% – 19.4%
**
*
*
*
*
*
Showing only countries with nationwide data.Data from 2004 for Poland and Romania and 2005 for
Ireland.Data representativeness unknown in countries marked with
an asterisk.
Treatment outcome New definite pulmonary cases, 2001-2005*
* Countries with representative outcome data. EU & West (culture positive): Andorra, Austria, Belgium, Czech Rep, Denmark, Estonia, Germany, Hungary, Iceland, Ireland, Israel, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden, United Kingdom. Balkans (smear positive): Albania, Macedonia F.Y.R. East (smear positive): Kazakhstan, Kyrgyzstan
0%
20%
40%
60%
80%
100%
2001 2002 2003 2004 2005 2001 2002 2003 2004 2005 2001 2002 2003 2004 2005
EU & West Balkans East
% cases
Success Died Failed or Still on treatment Defaulted, Transferred or Unknown
TB mortality rates, 2001-2006*
Not includedNo data or data incomplete< 1.1 1.1 – 5.0 5.1 – 10.0> 10.0
TB deaths per 100 000 population
Andorra
Malta
Monaco
San Marino * Source: WHO Mortality Database, October 2007. Data shown for latest available year. Including only deaths from TB coded ICD-9 010-018 or ICD-10 A15-19.